▽bexarotene - PubMed - NCBI ●01/08 13:12 Bexarotene: a clinical review.Farol LT, Hymes KB. Farol LT, et al. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. doi: 10.1586/14737140.4.2.180. Expert Rev Anticancer Ther. 2004. PMID: 15056048 Review.Bexarotene (Targretin, Ligand Pharmaceuticals Inc.) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids. ...Subs
▽AME-133v - PubMed - NCBI ●01/08 10:22 The future of CD20 monoclonal antibody therapy in B-cell malignancies.Czuczman MS, Gregory SA. Czuczman MS, et al. Leuk Lymphoma. 2010 Jun;51(6):983-94. doi: 10.3109/10428191003717746. Leuk Lymphoma. 2010. PMID: 20367564 Review.Preclinical and early clinical assessment of other novel anti-CD20 mAbs include: ocrelizumab, veltuzumab, GA101, AME-133v, and PRO131921; data suggest potential for impro
▽ABT-263 - PubMed - NCBI ●01/08 07:15 2025 5883 resultsPage of 89Navitoclax (ABT-263) Rejuvenates Human Skin by Eliminating Senescent Dermal Fibroblasts in a Mouse/Human Chimeric Model.Takaya K, Ishii T, Asou T, Kishi K. Takaya K, et al. Rejuvenation Res. 2023 Feb;26(1):9-20. doi: 10.1089/rej.2022.0048. Epub 2023 Jan 16. Rejuvenation Res. 2023. PMID: 36324221This study aimed to determine the rejuvenating effects of ABT-263 on agi
